Site-agnostic PARP-inhibitor maintenance therapy of advanced stage BRCA2-mutated gastric-type endocervical adenocarcinoma: A case report

  • 0Department of Obstetrics & Gynecology, Stanford University School of Medicine, Palo Alto, CA, United States.

Summary

No abstract available on PubMed